Value of PET/CT in the management of primary hepatobiliary tumors, part 2

American Journal of Roentgenology

Volumn 197, Issue 2, 2011, Pages

  Sacks, Ari ^a   Peller, Patrick J ^a   Surasi, Devaki S ^a   Chatburn, Luke ^a   Mercier, Gustavo ^a   Subramaniam, Rathan M ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatobiliary tumors; PET CT

Indexed keywords

ACETIC ACID C 11; FLUORODEOXYGLUCOSE F 18; GLUCOSE 6 PHOSPHATASE; GLUCOSE TRANSPORTER;

BILE DUCT CARCINOMA; CHOLANGIOGRAPHY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE SEVERITY; DRUG UPTAKE; ENZYME ACTIVITY; GALLBLADDER CANCER; GLUCOSE HOMEOSTASIS; HISTOPATHOLOGY; HUMAN; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CYST; LIVER FOCAL NODULAR HYPERPLASIA; LIVER HEMANGIOMA; LYMPH NODE METASTASIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ACETATES; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARBON RADIOISOTOPES; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FLUORODEOXYGLUCOSE F18; GALLBLADDER NEOPLASMS; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79960724829     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.6995     Document Type: Review

References (49)

1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127(suppl 1):S5-S16 (Pubitemid 39423365)
2. Oliveri F, Brunetto MR, Actis GC, Bonino F. Pathobiology of chronic hepatitis virus infection and hepatocellular carcinoma (HCC). Ital J Gastroenterol 1991; 23:498-502
3. Fabris C, Toniutto P, Falleti E, et al. MTHFR C677T polymorphism and risk of HCC in patients with liver cirrhosis: role of male gender and alcohol consumption. Alcohol Clin Exp Res 2009; 33:102-107
4. Murillas J, Del Río M, Riera M, et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16:113-115 (Pubitemid 40523054)
5. Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer 2006; 118:1591-1602 (Pubitemid 43376420)
6. Koike N, Cho A, Nasu K, et al. Role of diffusion-weighted magnetic resonance imaging in the differential diagnosis of focal hepatic lesions. World J Gastroenterol 2009; 15:5805-5812
7. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary- specific MR contrast agents: role in imaging the liver and biliary tree. RadioGraphics 2009; 29:1725-1748
8. Raddatz D, Ramadori G. Carbohydrate metabolism and the liver: actual aspects from physiology and disease. Z Gastroenterol 2007; 45:51-62 (Pubitemid 46202721)
9. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36:1811-1817
10. Salem N, MacLennan GT, Kuang Y, et al. Quantitative evaluation of 2-deoxy-2[F-18]fluoro-Dglucose-positron emission tomography imaging on the woodchuck model of hepatocellular carcinoma with histological correlation. Mol Imaging Biol 2007; 9:135-143 (Pubitemid 46705707)
11. Lee JD, Yang WI, Park YN, et al. Different glucose uptake and glycolytic mechanisms between hepatocellular carcinoma and intrahepatic mass-forming cholangiocarcinoma with increased (18) F-FDG uptake. J Nucl Med 2005; 46:1753-1759 (Pubitemid 46211600)
12. Roh MS, Jeong JS, Kim YH, Kim MC, Hong SH. Diagnostic utility of GLUT1 in the differential diagnosis of liver carcinomas. Hepatogastroenterology 2004; 51:1315-1318
13. Khan MA, Combs CS, Brunt EM, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32:792-797 (Pubitemid 30262739)
14. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003; 44:213-221
15. 18F]fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003; 69:117-124, discussion 124-126
16. Rose AT, Rose DM, Pinson CW, et al. Hepatocellular carcinoma outcomes based on indicated treatment strategy. Am Surg 1998; 64:1128-1134, discussion 1134-1135
17. Shiomi S, Nishiguchi S, Ishizu H, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001; 96:1877-1880
18. Kong YH, Han CJ, Lee SD, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose is useful for predicting the prognosis of patients with hepatocellular carcinoma (in Korean). Korean J Hepatol 2004; 10:279-287
19. 18F- fluorodeoxyglucose positron emission tomography in detecting extrahepatic metastasis in pretreatment staging of hepatocellular carcinoma. Oncology 2007; 72(suppl 1):104-110
20. Ho CL, Chen S, Yeung DW, Cheng TK. Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma. J Nucl Med 2007; 48:902-909 (Pubitemid 46909918)
21. Czernin J, Schelbert HR. PET/CT in cancer patient management: introduction. J Nucl Med 2007; 48(suppl 1):2S-3S
22. Iannaccone R, Piacentini F, Murakami T, et al. Hepatocellular carcinoma in patients with nonal-coholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology 2007; 243:422-430 (Pubitemid 46649697)
23. Kawaoka T, Aikata H, Takaki S, et al. FDG positron emission tomography/computed tomography for the detection of extrahepatic metastases from hepatocellular carcinoma. Hepatol Res 2009; 39:134-142
24. Delbeke D, Pinson CW. 11C-acetate: a new tracer for the evaluation of hepatocellular carcinoma. J Nucl Med 2003; 44:222-223
25. 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008; 49:1912-1921
26. 18F- fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver. Liver 2000; 20:487-490
27. Son HB, Han CJ, Kim BI, et al. Evaluation of various hepatic lesions with positron emission tomography (in Korean). Taehan Kan Hakhoe Chi 2002; 8:472-480
28. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510-515, discussion 515-516
29. Ishak K, Anthony PP, Sobin LH. Histological typing of tumours of the liver, 2nd ed. WHO international histological classification of tumours. New York, NY: Springer, 1994
30. 18F-FDG PET-CT in suspected and potentially operable cholangiocarcinoma: a prospective study compared with conventional imaging. Am J Gastroenterol 2008; 103:1145-1151
31. Petrowsky H, Wildbrett P, Husarik DB, et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006; 45:43-50 (Pubitemid 43850623)
32. Jadvar H, Henderson RW, Conti PS. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma. J Comput Assist Tomogr 2007; 31:223-228 (Pubitemid 46573360)
33. Kluge R, Schmidt F, Caca K, et al. Positron emission tomography with [(18)F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33:1029-1035 (Pubitemid 32378198)
34. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8:90-97 (Pubitemid 38117282)
35. Nakeeb A, Pitt HA, Sohn TA, et al. Cholangiocarcinoma: a spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996; 224:463-473, discussion 473-475
36. Li J, Kuehl H, Grabellus F, et al. Preoperative assessment of hilar cholangiocarcinoma by dual-modality PET/CT. J Surg Oncol 2008; 98:438-443
37. Kato T, Tsukamoto E, Kuge Y, et al. Clinical role of (18)F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur J Nucl Med Mol Imaging 2002; 29:1047-1054
38. 18F-FDG PET/CT: preliminary results for 22 patient studies. J Nucl Med 2005; 46:1158-1163
39. Seo S, Hatano E, Higashi T, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts lymph node metastasis, P-glycoprotein expression, and recurrence after resection in mass-forming intrahepatic cholangiocarcinoma. Surgery 2008; 143:769-777
40. 18F- fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas. J Gastroenterol Hepatol 2008; 23:759-765
41. 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003; 30:1467-1472
42. Ramos-Font C, Santiago Chinchilla A, Rodríguez- Fernández A, Rebollo Aquirre AC, Gómez Río M, Llamas Elvira JM. Gallbladder cancer staging with 18F-FDG PET-CT (in Spanish). Rev Esp Med Nucl 2009; 28:74-77
43. 18F- fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008; 206:57-65
44. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: DeVita VT Jr, Hellman S, Rosenberg SA (eds.). Cancer: principles and practice of oncology, 6th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001:1187-1202
45. Shukla PJ, Barreto SG, Arya S, et al. Does PETCT scan have a role prior to radical re-resection for incidental gallbladder cancer? HPB (Oxford) 2008; 10:439-445
46. Koh T, Taniguchi H, Yamaguchi A, Kunishima S, Yamagishi H. Differential diagnosis of gallbladder cancer using positron emission tomography with fluorine-18-labeled fluoro-deoxyglucose (FDG-PET). J Surg Oncol 2003; 84:74-81 (Pubitemid 37247912)
47. Rodríguez-Fernández A, Gómez Río M, Llamas Elvira JM, et al. Positron-emission tomography with fluorine-18-fluoro-2-deoxy- D-glucose for gallbladder cancer diagnosis. Am J Surg 2004; 188:171-175 (Pubitemid 38916738)
48. Oe A, Kawabe J, Torii K, et al. Distinguishing benign from malignant gallbladder wall thickening using FDG-PET. Ann Nucl Med 2006; 20:699-703 (Pubitemid 46155206)
49. 18F-FDG PET for the evaluation of gallbladder carcinoma. J Nucl Med 2006; 47:633-638